Australian contract manufacturing and packaging company, National ProPack, previously owned by National Chemicals Pty. Ltd., has become a wholly owned part of Australian contract manufacturing company TSI Pharmaceuticals, part of the global TSI Group. Specific terms of the deal were not disclosed.
The acquisition includes ProPack’s manufacturing facility in Brisbane providing TSI with expanded capacity to manufacture liquids and creams in topical format for therapeutic and Australian Pesticides and Veterinary Medicines Authority (APVMA) products, as well as industrial applications, in a wide variety of jars, tubes and bottles.
According to Ian Chant, TSI Pharmaceuticals managing director, the acquisition will strengthen TSI Pharmaceuticals product offerings, particularly related to the production of its locally made liquids and creams. Both National ProPack and TSI Pharmaceuticals are backed by the TSI Group, a global researcher, developer and manufacturer of ingredients and finished products with offices in Europe, Japan, China, Australia and the U.S.
As part of the TSI Group, ProPack will have the opportunity to offer customers the benefits of an expanded operation gaining access to worldwide innovation, economic purchasing and the vertical integration of closely controlled raw material manufacturers.
“This acquisition further fortifies TSI’s global supply chain strategy to manufacture in the country that provides our customers with the best quality, delivery performance and value,” said Chant.
ProPack owner Robert Bowser said his company was looking forward to providing clients an extended quality product offering made possible by the union of these two organizations.
“TSI is a strong organization which has experience managing product lines similar to ours and will certainly provide opportunities for growth,” Bowser said.